Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.

Abstract:

IMPORTANCE:Contrary to practice guidelines, breast magnetic resonance imaging (MRI) is commonly used in the preoperative evaluation of women with breast cancer. While existing literature has found little benefit to MRI in most patients, potential downstream consequences associated with breast MRI are not well described. OBJECTIVE:To describe patterns of preoperative breast MRI utilization in a health care system with universal insurance and its association with downstream investigations and clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS:This was a population-based retrospective cohort study using administrative heath care databases in Ontario, Canada (2012 population, 13.5 million) over 14 geographic regions were evaluated within the data set. Participants comprised 53 015 patients with primary operable breast cancer treated from 2003 to 2012. MAIN OUTCOMES AND MEASURES:Use of preoperative breast MRI by year, geographic region, and breast cancer stage. Postdiagnosis imaging, biopsy, and short-term surgical outcomes were also evaluated between those who did and did not receive MRI. RESULTS:Overall, 14.8% of patients (7824 of 53 015) had a preoperative MRI. During the 10-year study period, MRI use increased across all stages by 8-fold (from 3% to 24%; P < .001 for trend). Factors associated with MRI use were younger age, higher socioeconomic status, higher Charlson comorbidity score, surgery performed in a teaching hospital, and fewer years of surgeon experience. Multivariate analyses showed that preoperative breast MRI was associated with higher likelihood of the following: postdiagnosis breast imaging (odds ratio [OR], 2.09; 95% CI, 1.92-2.28), postdiagnosis breast biopsies (OR, 1.74; 95% CI, 1.57-1.93), postdiagnosis imaging to assess for distant metastatic disease (OR, 1.51; 95% CI, 1.42-1.61), mastectomy (OR, 1.73; 95% CI, 1.62-1.85), contralateral prophylactic mastectomy (OR, 1.48; 95% CI, 1.23-1.77), and a greater than 30-day wait to surgery (OR, 2.52; 95% CI, 2.36-2.70) (all ORs are adjusted). CONCLUSIONS AND RELEVANCE:Preoperative breast MRI use has increased substantially in routine clinical practice and is associated with a significant increase in ancillary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomies.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Arnaout A,Catley C,Booth CM,McInnes M,Graham I,Kumar V,Simos D,Van Walraven C,Clemons M

doi

10.1001/jamaoncol.2015.3018

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

1238-50

issue

9

eissn

2374-2437

issn

2374-2445

pii

2443152

journal_volume

1

pub_type

杂志文章
  • Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

    abstract:Importance:Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objective:To evaluate clinical outcomes when HAI chemotherapy is combined wit...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.3718

    authors: Cercek A,Boerner T,Tan BR,Chou JF,Gönen M,Boucher TM,Hauser HF,Do RKG,Lowery MA,Harding JJ,Varghese AM,Reidy-Lagunes D,Saltz L,Schultz N,Kingham TP,D'Angelica MI,DeMatteo RP,Drebin JA,Allen PJ,Balachandran VP,Lim

    更新日期:2019-10-31 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00

  • Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

    abstract:Importance:Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective:To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2016.3904

    authors: Melisko ME,Goldman ME,Hwang J,De Luca A,Fang S,Esserman LJ,Chien AJ,Park JW,Rugo HS

    更新日期:2017-03-01 00:00:00

  • The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

    abstract:IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6359

    authors: Péron J,Roy P,Ozenne B,Roche L,Buyse M

    更新日期:2016-07-01 00:00:00

  • Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

    abstract:Importance:Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient sele...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.2214

    authors: Dijkstra KK,Voabil P,Schumacher TN,Voest EE

    更新日期:2016-11-01 00:00:00

  • Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.

    abstract:Importance:Remarkable progress has occurred in understanding the pathophysiology and in developing improved personalized therapies in adult acute lymphoblastic leukemia (ALL). Observations:We searched MEDLINE (1990-2018), the American Society of Clinical Oncology, and American Society of Hematology websites (2010-2018...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1915

    authors: Jabbour E,Pui CH,Kantarjian H

    更新日期:2018-10-01 00:00:00

  • Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

    abstract:Importance:Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. Objective:To determine the frequency and spectrum of cancer susceptib...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.5194

    authors: Pearlman R,Frankel WL,Swanson B,Zhao W,Yilmaz A,Miller K,Bacher J,Bigley C,Nelsen L,Goodfellow PJ,Goldberg RM,Paskett E,Shields PG,Freudenheim JL,Stanich PP,Lattimer I,Arnold M,Liyanarachchi S,Kalady M,Heald B,Gre

    更新日期:2017-04-01 00:00:00

  • Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.

    abstract:Importance:Dietary fiber (the main source of prebiotics) and yogurt (a probiotic food) confer various health benefits via modulating the gut microbiota and metabolic pathways. However, their associations with lung cancer risk have not been well investigated. Objective:To evaluate the individual and joint associations ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.4107

    authors: Yang JJ,Yu D,Xiang YB,Blot W,White E,Robien K,Sinha R,Park Y,Takata Y,Lazovich D,Gao YT,Zhang X,Lan Q,Bueno-de-Mesquita B,Johansson I,Tumino R,Riboli E,Tjønneland A,Skeie G,Quirós JR,Johansson M,Smith-Warner SA

    更新日期:2020-02-01 00:00:00

  • The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

    abstract:Importance:For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that have been added to the t...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3381

    authors: Pinter M,Jain RK,Duda DG

    更新日期:2021-01-01 00:00:00

  • Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.

    abstract:Importance:Chemoradiotherapy (CRT), followed by surgery, is the recommended approach for stage II and III rectal cancer. While CRT decreases the risk of local recurrence, it does not improve survival and leads to poorer functional outcomes than surgery alone. Therefore, new approaches to better select patients for CRT ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.0186

    authors: Kennedy ED,Simunovic M,Jhaveri K,Kirsch R,Brierley J,Drolet S,Brown C,Vos PM,Xiong W,MacLean T,Kanthan S,Stotland P,Raphael S,Chow G,O'Brien CA,Cho C,Streutker C,Wong R,Schmocker S,Liberman S,Reinhold C,Kopek N

    更新日期:2019-07-01 00:00:00

  • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    abstract:Importance:Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. Objective:To examine the effect of multiple-gene sequencing on the experience and treatment ou...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0644

    authors: Kurian AW,Ward KC,Hamilton AS,Deapen DM,Abrahamse P,Bondarenko I,Li Y,Hawley ST,Morrow M,Jagsi R,Katz SJ

    更新日期:2018-08-01 00:00:00

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

    abstract:Importance:Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives:To i...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.3676

    authors: Ferrara R,Mezquita L,Texier M,Lahmar J,Audigier-Valette C,Tessonnier L,Mazieres J,Zalcman G,Brosseau S,Le Moulec S,Leroy L,Duchemann B,Lefebvre C,Veillon R,Westeel V,Koscielny S,Champiat S,Ferté C,Planchard D,Remon

    更新日期:2018-11-01 00:00:00

  • Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

    abstract:IMPORTANCE:E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratif...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2014.168

    authors: Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor N

    更新日期:2015-04-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

    abstract:IMPORTANCE:Instituting widespread measurement of outcomes for cancer hospitals using administrative data is difficult owing to lack of cancer-specific information such as disease stage. OBJECTIVE:To evaluate the performance of hospitals that treat patients with cancer using Medicare data for outcome ascertainment and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3151

    authors: Pfister DG,Rubin DM,Elkin EB,Neill US,Duck E,Radzyner M,Bach PB

    更新日期:2015-12-01 00:00:00

  • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

    abstract:Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this diseas...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.0219

    authors: Frezza AM,Jones RL,Lo Vullo S,Asano N,Lucibello F,Ben-Ami E,Ratan R,Teterycz P,Boye K,Brahmi M,Palmerini E,Fedenko A,Vincenzi B,Brunello A,Desar IME,Benjamin RS,Blay JY,Broto JM,Casali PG,Gelderblom H,Grignani G,

    更新日期:2018-09-01 00:00:00

  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

    abstract:Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.3361

    authors: Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

    更新日期:2018-05-01 00:00:00

  • Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

    abstract:Importance:Sarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown. ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0137

    authors: Caan BJ,Cespedes Feliciano EM,Prado CM,Alexeeff S,Kroenke CH,Bradshaw P,Quesenberry CP,Weltzien EK,Castillo AL,Olobatuyi TA,Chen WY

    更新日期:2018-06-01 00:00:00

  • Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.

    abstract:Importance:Primary tumor location is emerging as an important prognostic factor owing to distinct biological features. However, the side of origin of colon cancer (CC) still does not represent a prognostic parameter when deciding for adjuvant or palliative chemotherapy. Objective:To determine the prognostic role of le...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4227

    authors: Petrelli F,Tomasello G,Borgonovo K,Ghidini M,Turati L,Dallera P,Passalacqua R,Sgroi G,Barni S

    更新日期:2017-02-01 00:00:00

  • A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

    abstract:Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.5667

    authors: Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

    更新日期:2018-05-01 00:00:00

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.

    abstract:Importance:Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.6477

    authors: AlDubayan SH,Pyle LC,Gamulin M,Kulis T,Moore ND,Taylor-Weiner A,Hamid AA,Reardon B,Wubbenhorst B,Godse R,Vaughn DJ,Jacobs LA,Meien S,Grgic M,Kastelan Z,Markt SC,Damrauer SM,Rader DJ,Kember RL,Loud JT,Kanetsky PA,

    更新日期:2019-04-01 00:00:00

  • Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.

    abstract:IMPORTANCE:BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually. OBJECTIVE:To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3048

    authors: Armstrong J,Toscano M,Kotchko N,Friedman S,Schwartz MD,Virgo KS,Lynch K,Andrews JE,Aguado Loi CX,Bauer JE,Casares C,Bourquardez Clark E,Kondoff MR,Molina AD,Abdollahian M,Walker G,Sutphen R

    更新日期:2015-12-01 00:00:00

  • Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

    abstract:IMPORTANCE:Hepatocellular carcinoma (HCC) has the second-highest cancer-related mortality rate in the world because most patients are diagnosed at an intermediate to advanced stage when surgery is not suitable. Transcatheter arterial chemoembolization (TACE) is currently considered a first-line therapy for unresectable...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2015.2189

    authors: Huo YR,Eslick GD

    更新日期:2015-09-01 00:00:00

  • Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

    abstract:Importance:Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patient...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0250

    authors: He M,Li Q,Zou R,Shen J,Fang W,Tan G,Zhou Y,Wu X,Xu L,Wei W,Le Y,Zhou Z,Zhao M,Guo Y,Guo R,Chen M,Shi M

    更新日期:2019-07-01 00:00:00

  • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

    abstract:IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.5941

    authors: Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

    更新日期:2016-06-01 00:00:00

  • Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

    abstract:Importance:The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective:To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treat...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.1598

    authors: Suntharalingam M,Winter K,Ilson D,Dicker AP,Kachnic L,Konski A,Chakravarthy AB,Anker CJ,Thakrar H,Horiba N,Dubey A,Greenberger JS,Raben A,Giguere J,Roof K,Videtic G,Pollock J,Safran H,Crane CH

    更新日期:2017-11-01 00:00:00

  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

    abstract:Importance:Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective:To evaluate the association of pCR with event-free survival (EFS) and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2535

    authors: I-SPY2 Trial Consortium.,Yee D,DeMichele AM,Yau C,Isaacs C,Symmans WF,Albain KS,Chen YY,Krings G,Wei S,Harada S,Datnow B,Fadare O,Klein M,Pambuccian S,Chen B,Adamson K,Sams S,Mhawech-Fauceglia P,Magliocco A,Feldma

    更新日期:2020-09-01 00:00:00

  • Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer.

    abstract:Importance:Lay navigators in the Patient Care Connect Program support patients with cancer from diagnosis through survivorship to end of life. They empower patients to engage in their health care and navigate them through the increasingly complex health care system. Navigation programs can improve access to care, enhan...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6307

    authors: Rocque GB,Pisu M,Jackson BE,Kvale EA,Demark-Wahnefried W,Martin MY,Meneses K,Li Y,Taylor RA,Acemgil A,Williams CP,Lisovicz N,Fouad M,Kenzik KM,Partridge EE,Patient Care Connect Group.

    更新日期:2017-06-01 00:00:00

  • Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

    abstract:IMPORTANCE:The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large data...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.1184

    authors: Larkin J,Lao CD,Urba WJ,McDermott DF,Horak C,Jiang J,Wolchok JD

    更新日期:2015-07-01 00:00:00